Adherence
Tirzepatide and semaglutide produce similar reductions in fasting appetite and ad libitum energy intake during lunch, indicating that differences in weight loss between the two drugs are not explained by appetite suppression alone.
Both tirzepatide and semaglutide reduce hunger and calorie intake similarly during lunch. However, tirzepatide leads to more fat loss. This suggests that tirzepatide might work through additional mechanisms, such as increasing energy expenditure or changing how fat is stored, rather than just making you feel less hungry than semaglutide does.
Tirzepatide and semaglutide similarly reduced fasting appetite and energy intake during ad libitum lunch... Differences in energy intake during ad libitum lunch were not sufficient to explain the different weight outcomes.
Why this rating
Statistically significant reductions in appetite and intake were observed, but the comparison between active drugs showed no significant difference.
Source
Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes
Tim Heise et al. · Diabetes Care · 2023
DOI 10.2337/dc22-1710
Related findings · Adherence
- Regular physical activity (at least 150 minutes/week of moderate-intensity) reduces all-cause and cardiovascular mortality by 20-30% and lowers the risk of type 2 diabetes by 25-35%.Strong
- Increasing physical activity from a sedentary lifestyle to an active one in middle adulthood significantly reduces the risk of coronary events compared to remaining sedentary.Strong
- Resistance exercise is the only intervention capable of consistently restoring muscle function and strength in sarcopenia, partially overcoming age-related anabolic resistance.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →